Showing 1 - 2 results of 2, query time: 0.01s Refine Results
  1. 1
    Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022.

    Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022. by Anna Bratcher, Jefferson M Jones, William A Meyer, Rehan Waheed, Huda Yazgi, Aaron Harris, Adi V Gundlapalli, Kristie E N Clarke

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions—United States, 2020–2022

    Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions—United States, 2020–2022 by Anna Bratcher, Jefferson M. Jones, William A. Meyer, Rehan Waheed, Huda Yazgi, Aaron Harris, Adi V. Gundlapalli, Kristie E. N. Clarke

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: